IDEAYA Biosciences reported second quarter 2026 financial results on August 4, 2026. The company announced that its registrational OptimUM-02 trial for darovasertib in metastatic uveal melanoma met its primary endpoint, showing a median progression-free survival of 6.9 months versus 3.1 months for the control arm (HR: 0.42). An NDA filing is underway under the FDA's real-time oncology review program, with completion expected in H2 2026. Financially, collaboration revenue was $8.9 million, R&D expenses were $108.7 million, and net loss was $112.5 million. The company holds approximately $1.24 billion in cash following a June equity offering that raised $323.4 million. IDEAYA Biosciences operates in the biotechnology industry, focusing on the discovery and development of precision medicine oncology therapies.

IDEAYA Biosciences, Inc. closed a public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares. The offering, led by J.P. Morgan Securities LLC, representatives of the underwriters, and priced at $27.00 per share, generated approximately $323.6 million in net proceeds. IDEAYA Biosciences, Inc. is a biotechnology company focused on developing precision medicine for precision oncology.